$1m medical cannabis trial for skin cancer

Michael Reid 12 July 2016 4

Australia’s 50,000 melanoma sufferers could soon find relief through medical-grade cannabis as a result of a joint project involving the University of Canberra and a leading international pharmaceutical company.

The university has signed a $1 million collaboration with Cann Pharmaceutical to commence a medical-grade cannabis therapy trial for melanoma patients.

The two-year research project aims to produce a novel combination therapy treatment for some of the almost 50,000 Australians living with melanoma.

The research will be led by University of Canberra professor in molecular and cellular biology Sudha Rao, who is already conducting ground-breaking research to stop recurrence in breast cancer and other aggressive cancers.

Professor Rao said the project would help better inform the efficacy of medical cannabis-based treatments for melanoma.

“Australians have the highest rate of melanoma in the world, with estimates of more than 13,000 new cases to be diagnosed in 2016 alone,” Professor Rao said.

“When you consider that melanoma is the third most common cancer in Australia and New Zealand, and almost 1,800 people will die as a result of this cancer this year, we need to work harder at finding effective treatments.”

The identified strains of cannabis at the centre of the research have been developed by Israel-based Cann Pharmaceutical and will be coupled with the current standard care for melanoma patients.

Professor Rao’s team within the University’s Health Research Institute is already heading innovative research into aggressive cancers, such as breast cancer and developing treatments to switch off cancer stem cells and prevent cancer recurrence.

Acting vice-chancellor Professor Frances Shannon said the university was excited to be involved in this research and collaboration agreement.

“We are incredibly excited to take a leading research role into the application of medicinal cannabis for Australian patients,” Professor Shannon said.

“The support of Cann Pharmaceutical Australia, providing access to their medical-grade cannabis strains and funding worth $1 million is critical to taking this work from laboratory testing to clinical trials.”

The project is expected to commence the initial clinical trial phase within the ACT in 2017.

Cann Pharmaceutical is a recognised global leader in medical-grade cannabis, with nine years of operating experience producing the therapeutic drug for patients with intractable epilepsy, cancer, multiple sclerosis, Parkinsons and certain pain conditions.

ACT Greens MLA Shane Rattenbury welcomed the project’s announcement on Thursday, saying: “The Greens believe that medicinal cannabis should be available to sick and dying patients who need it, and have been driving this issue at both a local and national level.

“Today’s announcement is an important step in our long journey towards making medicinal cannabis a readily available treatment for a number of conditions, such as epilepsy, a range of different types of cancer and multiple sclerosis.

“The political debate about medicinal cannabis has gone on for some time now and I am really pleased that we are finally seeing movement on the ground that will help to relieve pain and suffering for many individuals.”

What's Your Opinion?

Please login to post your comments, or connect with
4 Responses to $1m medical cannabis trial for skin cancer
MarkE MarkE 12:44 pm 01 Jul 16

It is a policy of the Liberal Democratic Party to legalize cannabis for recreational and medical users.

Legalize, tax and regulate it like we currently regulate alcohol. There will be less violence with cannabis than alcohol.

gazket gazket 10:52 am 01 Jul 16

waste of 1 million $ . Nobody else has ever done a medical-grade cannabis therapy trial before where the info could be just looked up on the internet,

Masquara Masquara 10:48 am 01 Jul 16

I hope people understand that having a squamous cell burnt off your face won’t qualify you for medicinal cannabis!

Neil34 Neil34 10:21 pm 30 Jun 16

Welcome research and funding.

CBR Tweets

Sign up to our newsletter

Region Group Pty Ltd

Search across the site